BRAF and neoplasm: Systemic targeted treatments were delivered in three HER-negative cases, one within a clinical trial (olaparib followed by palbociclib), two owed to the evidence of actionable tumor mutations (1 tipifarnib for HRAS mutation, 1 dabrafenib and trametinib for BRAF mutation).